Insider · CIK 0001355537
Mihael Hristos Polymeropoulos
Files at VNDA (Vanda Pharmaceuticals Inc.). First filing May 19, 2025, latest Mar 4, 2026.
In brief
Mihael Hristos Polymeropoulos files SEC Form 4 as CEO, president and director at VNDA (Vanda Pharmaceuticals Inc.). Since May 19, 2025, Mihael Hristos Polymeropoulos has reported 3 open-market buys worth $170k and 1 open-market sell worth $1.3M, the latest filed on Mar 4, 2026.
A track record needs three past buys with six months of prices behind them; Mihael Hristos Polymeropoulos has 0, so none is measured yet.
The newest scored trade: sold $1.3M of VNDA on Mar 2, 2026, filed Mar 4, 2026, scored 65 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $1.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VNDA: Vanda Pharmaceuticals Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 65Notable | Vanda Pharmaceuticals Inc. | $1.3M 156,235 shares | -5% | +108% from low-8% from high | |
| 45Moderate | VNDAbuy Vanda Pharmaceuticals Inc. | $42k 10,000 shares | +0% | +7% from low-23% from high | |
| 35Weak | VNDAbuy Vanda Pharmaceuticals Inc. | $44k 10,000 shares | +0% | +10% from low-21% from high | |
| 43Moderate | VNDAbuy Vanda Pharmaceuticals Inc. | $84k 20,000 shares | +1% | +6% from low-24% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 2, 2026 | VNDA Vanda Pharmaceuticals Inc. | 156,235 0.26% of outstanding | $1.3M | Mar 2, 2026 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | VNDA Vanda Pharmaceuticals Inc. | SOpen-market sale Common Stock | -156,235 | $8.17 | $1.3M | 2,704,496 | Mar 4, 2026 |
| Feb 18, 2026 | VNDA Vanda Pharmaceuticals Inc. | AGrant or award Common Stock | +525,000 | $0.00 | $0 | 2,860,731 | Feb 19, 2026 |
| Aug 7, 2025 | VNDA Vanda Pharmaceuticals Inc. | POpen-market purchase Common Stock | +10,000 | $4.15 | $42k | 2,335,731 | Aug 8, 2025 |
| May 21, 2025 | VNDA Vanda Pharmaceuticals Inc. | POpen-market purchase Common Stock | +9,519 | $4.40 | $42k | 2,325,250 | May 21, 2025 |
| May 21, 2025 | VNDA Vanda Pharmaceuticals Inc. | POpen-market purchase Common Stock | +481 | $4.39 | $2,112 | 2,325,731 | May 21, 2025 |
| May 16, 2025 | VNDA Vanda Pharmaceuticals Inc. | POpen-market purchase Common Stock | +20,000 | $4.22 | $84k | 2,315,731 | May 19, 2025 |
Questions about Mihael Hristos Polymeropoulos
Answered from the filings on this page, as of the latest one.
Is Mihael Hristos Polymeropoulos buying or selling?
In the last 12 months Mihael Hristos Polymeropoulos reported 0 open-market buys worth $0 and 1 open-market sell worth $1.3M on SEC Form 4; the latest was sold $1.3M of VNDA on Mar 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Mihael Hristos Polymeropoulos's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mihael Hristos Polymeropoulos has 0.
Where does Mihael Hristos Polymeropoulos file Form 4?
Mihael Hristos Polymeropoulos has filed Form 4 at VNDA (Vanda Pharmaceuticals Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.